BTIG analyst Mark Massaro lowered the firm’s price target on MDxHealth (MDXH) to $6 from $8 and keeps a Buy rating on the shares. The company is an attractive small-cap growth and value stock and a one-stop-shop in personalized prostate diagnostics testing, though the firm is updating its model to bake in some dilution from MDxHealth’s recent $40M public offering, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH: